- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/30 - Phthalazines
Patent holdings for IPC class C07D 237/30
Total number of patents in this class: 89
10-year publication summary
|
0
|
10
|
4
|
2
|
4
|
7
|
9
|
7
|
1
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Amgen Inc. | 4425 |
6 |
| Sitryx Therapeutics Limited | 48 |
6 |
| Shanghai Yingli Pharmaceutical Co., Ltd. | 50 |
4 |
| Agc, Inc. | 5502 |
4 |
| Impetis Biosciences Ltd. | 30 |
3 |
| Novartis AG | 10263 |
2 |
| Bristol-myers Squibb Company | 4729 |
2 |
| BASF SE | 21303 |
2 |
| AstraZeneca AB | 2818 |
2 |
| Centre National de La Recherche Scientifique | 11016 |
2 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3337 |
2 |
| MetrioPharm AG | 52 |
2 |
| Universite de Montpellier | 1042 |
2 |
| Universite de Strasbourg | 711 |
2 |
| Disarm Therapeutics, Inc. | 55 |
2 |
| Tyra Biosciences, Inc. | 59 |
2 |
| Biodol Therapeutics | 5 |
2 |
| Desai, Laxman S. | 3 |
2 |
| Eikonizo Therapeutics, Inc. | 21 |
2 |
| Genentech, Inc. | 4099 |
1 |
| Other owners | 37 |